Last reviewed · How we verify
Plegisol In Plastic Container (Sodium Chloride)
Provides isotonic saline irrigation with mechanical cleansing action for sterile irrigation of body cavities, tissues, wounds, and surgical equipment.
Sodium Chloride Irrigation, USP is a sterile, nonpyrogenic isotonic saline solution indicated for general irrigation, washing, rinsing, and dilution purposes including blood cell washing. The solution provides sodium and chloride ions essential for maintaining fluid and electrolyte balance and is considered compatible with living tissues and organs. Primary contraindications include prohibition from injection by usual parenteral routes and avoidance during electrosurgical procedures. The product serves as a mechanical cleansing agent and vehicle for pharmaceutical preparations in surgical and clinical settings.
At a glance
| Generic name | Sodium Chloride |
|---|---|
| Sponsor | Baxter |
| Drug class | Electrolyte solution |
| Target | Not specified |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1965 |
Mechanism of action
Sodium Chloride Irrigation, USP is an isotonic saline solution identical in composition to 0.9% Sodium Chloride Injection, USP (normal saline). The solution dissociates to provide sodium (Na+) and chloride (Cl−) ions. Sodium is the principal cation of extracellular fluid and plays a large role in therapy of fluid and electrolyte disturbances, while chloride has an integral role in buffering action during oxygen and carbon dioxide exchange in red blood cells. The solution is considered generally compatible with living tissues and organs. Distribution and excretion of sodium and chloride are largely controlled by the kidney, which maintains balance between intake and output. Water, an essential constituent of all body tissues accounting for approximately 70% of total body weight, is maintained through various regulatory mechanisms, with sodium playing a major role in maintaining physiologic equilibrium.
Approved indications
Common side effects
- COVID-19
- Headache
- Fatigue
- Injection site pain
- Chills
- Pain
- Myalgia
- Pyrexia
- Upper respiratory tract infection
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- Modified Tumor-free Techniques Operation to Cervical Cancer (NA)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- PRP Injection Into the Sacroiliac Joint After Ipsilateral THA: Effects on Early Recovery and Function (SIJ-THA Randomized Trial) (NA)
- Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Plegisol In Plastic Container CI brief — competitive landscape report
- Plegisol In Plastic Container updates RSS · CI watch RSS
- Baxter portfolio CI